Alcon Inc. (ALC)
NYSE: ALC · Real-Time Price · USD
94.52
-1.25 (-1.31%)
Mar 31, 2025, 9:42 AM EDT - Market open
Alcon Revenue
In the year 2024, Alcon had annual revenue of $9.91B with 4.82% growth. Alcon had revenue of $2.50B in the quarter ending December 31, 2024, with 6.38% growth.
Revenue (ttm)
$9.91B
Revenue Growth
+4.82%
P/S Ratio
4.78
Revenue / Employee
$387,164
Employees
25,599
Market Cap
47.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.91B | 456.00M | 4.82% |
| Dec 31, 2023 | 9.46B | 738.00M | 8.47% |
| Dec 31, 2022 | 8.72B | 426.00M | 5.14% |
| Dec 31, 2021 | 8.29B | 1.46B | 21.34% |
| Dec 31, 2020 | 6.83B | -675.00M | -8.99% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
ALC News
- 4 days ago - Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease - Business Wire
- 4 days ago - LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR - Business Wire
- 6 days ago - Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities - Business Wire
- 7 days ago - Alcon Agrees to Acquire LENSAR, Inc. - Business Wire
- 7 days ago - Retinal Surgery Devices Market Outlook Report 2025-2033: Revenues Set to Double, Reaching $4.83 Billion by 2033, Led by Topcon Corp., Alcon, and Carl Zeiss - GlobeNewsWire
- 18 days ago - Alcon to Host 2025 Capital Markets Day - Business Wire
- 4 weeks ago - Alcon Canada Strengthens its Commitment to Astigmatic Patients with TOTAL30 for Astigmatism Expanded Parameters - Business Wire
- 4 weeks ago - Alcon Inc. (ALC) Q4 2024 Earnings Call Transcript - Seeking Alpha